RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here
In 52 patients with moderate–severe RA on stable csDMARDs, oral GSK2982772 60 mg for 84 days was mainly assessed for safety; DAS28-CRP and ACR responses looked similar to placebo, without meaningful clinical improvement at tested exposures.
Source
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis
Study at a glance
- Design
- RCT — Multicenter double-blind placebo-controlled experimental-medicine RCT; 2:1 drug:placebo for 84 days on stable csDMARD
- N
- N=52 · 34 GSK2982772 60 mg, 18 placebo
- Population
- Adults with rheumatoid arthritis on stable conventional DMARD therapy
- Outcome
- Safety/PK and preliminary DAS28-CRP / ACR efficacy
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Multicenter randomized, double-blind (sponsor-unblinded), placebo-controlled experimental-medicine study randomized patients 2:1 to GSK2982772 60 mg or placebo orally 2–3 times daily for 84 days while on ≥12 weeks stable csDMARD therapy, assessing safety/PK and preliminary efficacy (DAS28-CRP, ACR responses).
What they found
52 patients were randomized (34 drug, 18 placebo). Safety was the primary objective; efficacy scores and low-disease-activity/remission rates were similar between arms. Authors conclude RIPK1 inhibition at the evaluated exposures did not translate into meaningful clinical improvement.
The limits
What it doesn't show
A null mean efficacy signal at these exposures is not proof that all RIPK1 strategies fail forever or that higher/longer regimens cannot work. Small experimental-medicine n limits precision. Safety findings still matter for pathway development.
Key terms
- RIPK1
- Receptor-interacting protein kinase 1 — inflammatory/cell-death mediator targeted by GSK2982772.
- Experimental medicine study
- Early clinical study focused on safety/PK/PD with preliminary efficacy signals.
- DAS28-CRP
- Disease activity composite used as a key clinical score here.
- ACR20/50/70
- Standard RA response thresholds compared between arms.
- csDMARD background
- Stable conventional synthetic DMARD therapy required before randomization.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Primary objective?
Common questions
What drug was tested?
GSK2982772, an oral RIPK1 inhibitor.
How many patients?
52 randomized (34 active, 18 placebo).
Primary focus?
Safety and tolerability (with PK and preliminary efficacy).
Did activity scores beat placebo?
DAS28-CRP and ACR responses were similar between arms — no meaningful clinical improvement at tested exposures.
Who could enroll?
Moderate–severe RA on stable csDMARD therapy for ≥12 weeks.
More on Rheumatology